Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, ...

Q2 2025 Earnings Call Transcript August 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.07, ...

Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine ...

The stop order came on Aug. 5, the same day Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine projects under ...

ISS and Glass Lewis, leading independent proxy advisory firms, support reverse stock split proposal - - Webcast to begin at 4:30 p.m. ET / 1:30 p.m. PT - SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 ...

Vaxart Inc (VXRT) reports a significant revenue increase but faces hurdles with trial suspensions and NASDAQ compliance ...

Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc.

Analysts estimate that Vaxart will report an earnings per share (EPS) of $-0.10. The announcement from Vaxart is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

The company is not developing an mRNA vaccine, but had been using one as the control in a 10,000-subject Phase IIb trial.

Vaxart’s board has also approved a proportional reduction in the authorized number of shares, contingent upon shareholder approval of the reverse stock split. 3rd party Ad.

--Vaxart, Inc., a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it filed a preliminary proxy ...

Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV ...